Characterizing tumor shrinkage as a measure of clinical benefit for immune checkpoint inhibitors

BACKGROUND: We explored whether the effectiveness of immune checkpoint inhibitors (ICIs) can be characterized by incorporating a composite of duration of response (DOR) to complement traditional Response Evaluation Criteria in Solid Tumors (RECIST) criteria for objective response rate (ORR) in an in...

Descripción completa

Detalles Bibliográficos
Autores principales: Kelleher, Thomas, Cai, Junliang, Botwood, Nicholas AJ, Labriola, Dominic F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7871697/
https://www.ncbi.nlm.nih.gov/pubmed/33558277
http://dx.doi.org/10.1136/jitc-2020-001177

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7871697/
https://www.ncbi.nlm.nih.gov/pubmed/33558277
http://dx.doi.org/10.1136/jitc-2020-001177

Ejemplares similares